SCHEMBL5711092

SCHEMBL5711092

O/N=C/Nc1ccc(OCc2ccccn2)nc1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 9/20 0.49
HTR2B P41595 7/20 0.46
HTR2A P28223 5/20 0.46
SMN1; SMN2 Q16637 3/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
LMNA P02545 1/20 0.39
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
ABCB1 P08183 1/20 0.36
HTR1A P08908 1/20 0.36
DRD2 P14416 1/20 0.36
PARP10 Q53GL7 1/20 0.36
SYK P43405 2/20 0.36
ALOX15 P16050 1/20 0.36
AURKB Q96GD4 1/20 0.35
INCENP Q9NQS7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5711093 1.00 HTR2C (0.49) HTR2CHTR2BHTR2ASMN1; SMN2NPC1
SCHEMBL6285192 0.83 SMN1; SMN2 (0.54) HTR2CHTR2BHTR2ASMN1; SMN2NPC1
SCHEMBL5720536 0.83 SMN1; SMN2 (0.54) HTR2CHTR2BHTR2ASMN1; SMN2NPC1
SCHEMBL7539295 0.72 HTR2C (0.57) HTR2CHTR2BHTR2ASMN1; SMN2NPC1
SCHEMBL29417058 0.71 ALDH1A1 (0.68) HTR2CHTR2BHTR2ASMN1; SMN2NPC1
SCHEMBL13052590 0.71 ALDH1A1 (0.68) HTR2CHTR2BHTR2ASMN1; SMN2NPC1
SCHEMBL30716906 0.70 SYK (0.54) HTR2CHTR2BHTR2ASMN1; SMN2KDM4E
SCHEMBL13661860 0.70 SYK (0.54) HTR2CHTR2BSMN1; SMN2KDM4EALDH1A1
SCHEMBL4235232 0.70 SYK (0.54) HTR2CHTR2BHTR2ASMN1; SMN2KDM4E
SCHEMBL11354880 0.70 SMN1; SMN2 (0.51) SMN1; SMN2NPC1RAB9ALMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1291343-B1 HYDROXYFORMAMIDINE DERIVATIVES AND MEDICINES CONTAINING THE SAME TAISHO PHARMACEUTICAL CO LTD (JP) 2006-12-06 EP disclosed
US-6670382-B2 For inhibiting a synthase of 20-hydroxyeicosatetraenoic acid biosynthesized from arachidonic acid involved in constriction or dilation of microvessels in the kidneys and the cerebral blood vessels, or participates in cell proliferation TAISHO PHARMACEUTICAL CO., LTD. (JP) 2003-12-30 US disclosed
US-20030186979-A1 Hydroxyformamidine derivatives and medicines containing the same TAISHO PHARMACEUTICAL CO., LTD. (JP) 2003-10-02 US disclosed
EP-1291343-A1 HYDROXYFORMAMIDINE DERIVATIVES AND MEDICINES CONTAINING THE SAME TAISHO PHARMACEUTICAL CO., LTD (JP) 2003-03-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186979-A1 Hydroxyformamidine derivatives and medicines containing the same HTR3E, PGF, VEGFA HTR2C 23/4885HTR2B 67/4885HTR2A 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.